NEW YORK (GenomeWeb) – Rosetta Genomics today announced that its sales partner Admera Health has received approval from the New Jersey Department of Health (NJDH) for the OncoGxSelect panel for clinical use.

Admera's next-generation sequencing-based oncology panel looks at five genes associated with lung cancer. The test detects point mutations, small indels, and gene fusions in KRAS, BRAF, EGFR, ROS1, and ALK to provide clinically actionable results. OncoGxSelect is performed on formalin-fixed, paraffin-embedded tissue samples.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

While gene therapies may have high price tags, they could be cheaper than the cost of managing disease, according to MIT's Technology Review.

Researchers are looking for markers that indicate which cancer patients may respond to immunotherapies, the Associated Press writes.

In Nature this week: paternal age associated with de novo mutations in children, and more.

Nature News writes that researchers are still wrangling over the role of the p-value.